Molecular Docking Studies on Isolated and Characterized Compounds of Marine and Plant Origin with Antidiabetic Activity

Emmanuel Ebuka Abonyi; Okafor Sunday; Victor Onyekachi Eze; Akodu Busayo Odunayo; Azike Ruth Chinazor; Ogbuagu Ngozi Eunice

Molecular Docking Studies on Isolated and Characterized Compounds of Marine and Plant Origin with Antidiabetic Activity

Emmanuel Ebuka Abonyi

Okafor Sunday

Victor Onyekachi Eze

Akodu Busayo Odunayo

Azike Ruth Chinazor

Ogbuagu Ngozi Eunice

South Asian Research Journal of Natural Products, Page 11-31

Published: 1 October 2022

Abstract

Introduction: Diabetics Mellitus is a chronic disease characterized by hyperglycemia and disturbance in protein and fat metabolism. This study was carried out to determine the binding affinity of some marine and plant-derived compounds earlier reported through molecular docking studies, and also to evaluate the physicochemical, pharmacokinetic and toxicity profiles of these compounds.

Methods: The identified compounds with antidiabetic activities from the literature were subjected to virtual screening and rigid molecular docking in order to evaluate their binding affinity with the human PPAR alpha ligand binding domain (PDB Code: 3VI8) as the target. MMFF94 force field was used for energy minimization of the ligand molecule. The prepared compounds were then subjected to interact with the receptor through molecular docking. The toxicity, pharmacokinetics and physicochemical profiles were established using online webservers Protox 11 and SwissADME.

Results: Compounds; 6, 7, 12, 32, 66, 80, 89, 121, 138 and, 139 showed greater binding affinity with PPARy target protein with free binding energy of (-6.2 to 8.1kcal/ mol) comparable to the standard drug with 5.2kcal/mol. Similarly, the selected compounds possess acceptable physicochemical and toxicity profiles with potential for good oral bioavailability.

Conclusion: Ten (10) compounds extracted from seven (7) naturally occurring (marine) species were found as potential peroxisome proliferators-activated receptor gamma (PPARγ) agonist with promising antidiabetic activity. The in-silico studies confirmed that the 10 selected compounds have strong binding interactions with the drug receptors and therefore possess anti diabetic activity.

Keywords:

Antidiabetic activity
marine and plant-derived
molecular docking
PPARy
physicochemical

How to Cite

Abonyi, E. E., Sunday, O., Eze, V. O., Odunayo, A. B., Chinazor, A. R., & Eunice, O. N. (2022). Molecular Docking Studies on Isolated and Characterized Compounds of Marine and Plant Origin with Antidiabetic Activity. South Asian Research Journal of Natural Products, 5(3), 11-31. Retrieved from https://journalsarjnp.com/index.php/SARJNP/article/view/94

References

Mannino GC, Andreozzi F, Sesti G. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. Diabetes Metab Res Rev. 2019; 35(3):e3109.

DOI: 10.1002/dmrr.3109, PMID 30515958.

Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem. 2009;17(5):1783-802.

DOI: 10.1016/j.bmc.2009.01.061, PMID 19217790.

Song CM, Lim SJ, Tong JC. Recent advances in computer-aided drug design. Brief Bioinform. 2009;10(5):579-91.

DOI: 10.1093/bib/bbp023, PMID 19433475.

Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586-93.

DOI: 10.1007/s00125-017-4336-x, PMID 28770321.

Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN. Thiazolidinediones as antidiabetic agents: A critical review. Bioorg Chem. 2018;77:548-67.

DOI: 10.1016/j.bioorg.2018.02.009, PMID 29475164.

Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN. Thiazolidinediones as antidiabetic agents: A critical review. Bioorg Chem. 2018;77:548-67.

DOI: 10.1016/j.bioorg.2018.02.009, PMID 29475164.

Marchetti P, Lupi R, Del Guerra S, Bugliani M, D’Aleo V, Occhipinti M, et al. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Diabetes Care. 2009;32;Suppl 2:S178-83.

DOI: 10.2337/dc09-S306, PMID 19875548.

Mohler ML, He Y, Wu Z, Hwang DJ, Miller DD. Recent and emerging anti-diabetes targets. Med Res Rev. 2009;29(1):125-95.

DOI: 10.1002/med.20142, PMID 18855890.

Evans JL, Jallal B. Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Expert Opin Investig Drugs. 1999;8(2):139-60.

DOI: 10.1517/13543784.8.2.139, PMID 15992069.

Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science {(New}. NY: York. 1999;283(5407):1544-8.

Carpino PA, Goodwin B. Diabetes area participation analysis: A review of companies and targets described in the 2008-2010 patent literature. Expert Opin Ther Pat. 2010;20(12):1627-51.

DOI: 10.1517/13543776.2010.533171, PMID 21083519.

Viljoen A, Sinclair AJ. Diabetes and insulin resistance in older people. Med Clin North Am. 2011;95(3):615-29.

DOI: 10.1016/j.mcna.2011.02.003, PMID 21549881.

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615-23.

DOI: 10.1021/jm020017n, PMID 12036371.

Schwanstecher C, Schwanstecher M. Targeting type 2 diabetes. In: Schwanstecher M, editor. Diabetes – perspectives in drug therapy. Berlin, Heidelberg: Springer Berlin Heidelberg. 2011;1-33.

Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des. 2003;9(11):891-902.

DOI: 10.2174/1381612033455279, PMID 12678873.

Brown D, Superti-Furga G. Rediscovering the sweet spot in drug discovery. Drug Discov Today. 2003;8(23):1067-77.

DOI: 10.1016/s1359-6446(03)02902-7, PMID 14693466.

Zhang S, Lu W, Liu X, Diao Y, Bai F, et al. Fast and effective identification of the bioactive compounds and their targets from medicinal plants via computational chemical biology approach. Med.chem.Commun. 2011;2(6):471-7.

Veselovsky AV, Ivanov AS. Strategy of computer-aided drug design. Curr Drug Targets Infect Disord. 2003;3(1):33-40.

DOI: 10.2174/1568005033342145, PMID 12570731.

Salam NK, Nuti R, Sherman W. Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model. 2009;49(10): 2356-68.

DOI: 10.1021/ci900212v, PMID 19761201.

Kumar P, Choonara YE, Pillay V. In silico affinity profiling of neuroactive polyphenols for post-traumatic calpain inactivation: A molecular docking and atomistic simulation sensitivity analysis. Molecules. 2014;20(1): 135-68.

DOI: 10.3390/molecules20010135. PMID 25546626.

Egbujor MC, Okoro UC, Okafor S. Design, synthesis, molecular docking, antimicrobial, and antioxidant activities of New Phenylsulfamoyl carboxylic acids of pharmacological interest. Med Chem Res. 2019;28(12): 2118-27.

DOI: 10.1007/s00044-019-02440-3.

296 times
35 times